(Yicai Global) July 18 -- Britain's biggest drug company GlaxoSmithKline Plc.'s Cervarix® vaccine has been licensed by the China Food and Drug Administration, the company said. It becomes the first human papillomavirus types 16 and 18 vaccine against cervical cancer approved to enter the Chinese market.
HPV types 16 and 18 cause 70 percent of cervical cancers in women. The first HPV vaccine was released globally in 2006 and huge progress has since been made in stemming the spread of the disease.